GLOBE1 lentiviral vector expressing βAS3 globin
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GLOBE1 lentiviral vector expressing βAS3 globin, covering 2026-03-05 to 2026-03-05. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE) [Phase 1, Phase 2]